Involvement of Anterior Visual Pathway in Early Multiple Sclerosis

Visual evoked potentials and optical coherence tomography confirm subclinical disease.

According to the 2017 McDonald criteria for diagnosing multiple sclerosis (MS), tests of the anterior visual pathway could provide objective evidence of neurologic involvement but do not currently contribute to criteria for dissemination in space and dissemination in time. The McDonald criteria expert panel designated validation studies of the anterior visual pathway as a high priority for future refinements. To better understand the sensitivity and specificity of these ancillary tests, investigators enrolled 150 patients with either clinically isolated syndrome (CIS) or early MS.

Subclinical visual evoked potential (VEP) abnormalities were found in 19% of CIS patients. Subclinical optical coherence tomography abnormalities were found in 4.5…

Reviewing Author

Robert T. Naismith, MD

Disclosures

Consultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics

Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense

Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)

Robert T. Naismith, MD

Disclosures

Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense

Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)

Involvement of Anterior Visual Pathway in Early Multiple Sclerosis

Topics

Reviewing Author